Core Insights - BioAge Labs is advancing its clinical pipeline with the oral NLRP3 inhibitor BGE-102, set to initiate Phase 1 trials in the second half of 2025, with initial data expected by year-end [2][3] - The company has expanded its APJ agonist pipeline through a partnership for potent antibodies and has filed patents for novel oral small molecules [2][7] - BioAge is enhancing its discovery platform by profiling over 17,000 samples from the HUNT Biobank, which will generate millions of data points related to human longevity [5] Clinical Pipeline Development - The BGE-102 program has completed IND-enabling studies and has shown significant weight loss in preclinical models, both as a standalone treatment and in combination with semaglutide [3] - The Phase 1 SAD/MAD clinical trial for BGE-102 is planned for the second half of 2025, with initial SAD data anticipated by the end of the year [3][13] APJ Agonist Pipeline Expansion - BioAge entered an exclusive option agreement with JiKang Therapeutics to potentially in-license a novel APJ agonist nanobody, which is reported to have over 10-fold greater potency than apelin [7] - The company has filed a U.S. provisional patent for a new class of orally active APJ agonists with high solubility and metabolic stability [7] Discovery Platform Expansion - BioAge's collaboration with the HUNT Biobank aims to profile over 17,000 samples from more than 6,000 participants, generating extensive molecular measurements over decades [5] - The partnership provides BioAge exclusive access to the data for drug discovery purposes [5] Financial Performance - For Q2 2025, research and development expenses were $19.8 million, up from $10.5 million in Q2 2024, primarily due to increased costs related to licensing and development activities [9] - General and administrative expenses rose to $7.3 million from $4.8 million in the same period last year, driven by higher personnel-related expenses [10] - The net loss for Q2 2025 was $21.6 million, or $0.60 per share, compared to a net loss of $13.6 million, or $7.94 per share, in Q2 2024 [11] Cash Position - As of June 30, 2025, BioAge had approximately $313.4 million in cash, cash equivalents, and marketable securities, which is expected to fund operations through 2029 [12]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased BioAge Labs, Inc. stock during its IPO on September 26, 2024, of the March 10, 2025, deadline to become a lead plaintiff in a class action lawsuit related to the company's alleged misleading statements regarding its clinical trials [1]. Group 1: Class Action Details - Investors who purchased BioAge stock may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, investors can visit the provided link or contact the law firm for more information [3][7]. - A class action lawsuit has already been filed, and interested parties must act by March 10, 2025, to serve as lead plaintiff [3]. Group 2: Background of the Case - The lawsuit claims that BioAge misrepresented the safety and efficacy of its lead product candidate, azelaprag, in connection with the STRIDES clinical trial, which was expected to yield topline results in 2025 [5]. - BioAge's collaboration with Eli Lilly's Chorus clinical development organization was highlighted as part of the trial's design and execution [5]. - The IPO suggested no safety concerns, but the company later discontinued the STRIDES Phase 2 study due to elevated liver enzyme levels in subjects, indicating potential organ damage [6]. Group 3: Allegations of Misleading Information - The lawsuit alleges that BioAge failed to disclose the potential for liver transaminitis from previous clinical trials and preclinical studies, making their statements in the registration statement materially misleading at the time of the IPO [6]. - When the true details about the safety concerns became public, investors reportedly suffered damages [6].

Core Viewpoint - BioAge Labs, Inc. is facing a class action lawsuit following the discontinuation of its STRIDES Phase 2 trial for azelaprag due to safety concerns, which led to a significant drop in its stock price [2]. Group 1: Lawsuit Details - The lawsuit is on behalf of shareholders who purchased BioAge stock during the class period related to its IPO on September 26, 2024 [1]. - The discontinuation of the STRIDES Phase 2 trial was announced on December 6, 2024, due to elevated liver transaminase levels, causing the stock price to plummet from $20.09 to $4.65 within a day [2]. Group 2: Shareholder Actions - Shareholders are encouraged to register for the class action by March 10, 2025, to potentially become lead plaintiffs [3]. - Registered shareholders will receive updates through a portfolio monitoring software regarding the case's progress [3]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [4].

Core Viewpoint - BioAge Labs, Inc. is facing a class action lawsuit following the discontinuation of its STRIDES Phase 2 trial for azelaprag due to safety concerns, which led to a significant drop in its stock price [2]. Group 1: Lawsuit Details - The lawsuit is on behalf of shareholders who purchased BioAge stock during the class period related to its IPO on September 26, 2024 [1]. - The complaint alleges that BioAge's announcement on December 6, 2024, regarding the discontinuation of the azelaprag trial was unexpected, as the company had previously promoted the drug's potential [2]. - Following the announcement, BioAge's stock price plummeted from $20.09 per share to $4.65 per share within a day [2]. Group 2: Shareholder Actions - Shareholders are encouraged to register for the class action by March 10, 2025, to potentially become lead plaintiffs [3]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the case's progress [3]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [4]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors affected by misleading statements [4].